BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
53.31
+0.32 (0.60%)
At close: Dec 12, 2025, 4:00 PM EST
53.31
0.00 (0.00%)
After-hours: Dec 12, 2025, 5:57 PM EST
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $776.13M in the quarter ending September 30, 2025, with 4.08% growth. This brings the company's revenue in the last twelve months to $3.09B, up 12.39% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.09B
Revenue Growth
+12.39%
P/S Ratio
3.30
Revenue / Employee
$1,017,763
Employees
3,040
Market Cap
10.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | 1.70B | 212.84M | 14.27% |
| Dec 31, 2018 | 1.49B | 177.57M | 13.52% |
| Dec 31, 2017 | 1.31B | 196.79M | 17.62% |
| Dec 31, 2016 | 1.12B | 226.96M | 25.50% |
| Dec 31, 2015 | 889.90M | 140.61M | 18.77% |
| Dec 31, 2014 | 749.28M | 200.80M | 36.61% |
| Dec 31, 2013 | 548.49M | 47.76M | 9.54% |
| Dec 31, 2012 | 500.72M | 59.37M | 13.45% |
| Dec 31, 2011 | 441.36M | 65.09M | 17.30% |
| Dec 31, 2010 | 376.27M | 51.61M | 15.90% |
| Dec 31, 2009 | 324.66M | 28.16M | 9.50% |
| Dec 31, 2008 | 296.49M | 174.91M | 143.86% |
| Dec 31, 2007 | 121.58M | 37.37M | 44.38% |
| Dec 31, 2006 | 84.21M | 58.54M | 228.06% |
| Dec 31, 2005 | 25.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BMRN News
- 24 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England - PRNewsWire
- 6 weeks ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 6 weeks ago - Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - The Motley Fool
- 6 weeks ago - Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings - Benzinga
- 6 weeks ago - BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations - Seeking Alpha
- 6 weeks ago - BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - BioMarin Pharma plans to divest struggling gene therapy - Reuters